- Home
- LTRN vs LPCN Comparison
LTRN vs LPCN Comparison
Compare LTRN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRN
- LPCN
- Stock Information
- Founded
- LTRN 2013
- LPCN 1997
- Country
- LTRN United States
- LPCN United States
- Employees
- LTRN N/A
- LPCN N/A
- Industry
- LTRN Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- LTRN Health Care
- LPCN Health Care
- Exchange
- LTRN Nasdaq
- LPCN Nasdaq
- Market Cap
- LTRN 33.7M
- LPCN 27.1M
- IPO Year
- LTRN 2020
- LPCN N/A
- Fundamental
- Price
- LTRN $4.48
- LPCN $4.39
- Analyst Decision
- LTRN Hold
- LPCN Strong Buy
- Analyst Count
- LTRN 1
- LPCN 1
- Target Price
- LTRN N/A
- LPCN $10.00
- AVG Volume (30 Days)
- LTRN 69.9K
- LPCN 32.5K
- Earning Date
- LTRN 03-17-2025
- LPCN 03-06-2025
- Dividend Yield
- LTRN N/A
- LPCN N/A
- EPS Growth
- LTRN N/A
- LPCN N/A
- EPS
- LTRN N/A
- LPCN N/A
- Revenue
- LTRN N/A
- LPCN $7,922,926.00
- Revenue This Year
- LTRN N/A
- LPCN N/A
- Revenue Next Year
- LTRN N/A
- LPCN N/A
- P/E Ratio
- LTRN N/A
- LPCN N/A
- Revenue Growth
- LTRN N/A
- LPCN N/A
- 52 Week Low
- LTRN $2.79
- LPCN $3.20
- 52 Week High
- LTRN $11.99
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- LTRN 66.50
- LPCN 40.74
- Support Level
- LTRN $3.48
- LPCN $4.25
- Resistance Level
- LTRN $3.97
- LPCN $4.73
- Average True Range (ATR)
- LTRN 0.44
- LPCN 0.35
- MACD
- LTRN 0.06
- LPCN -0.05
- Stochastic Oscillator
- LTRN 76.50
- LPCN 11.20
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.